Clinical Trial to Assess the Relative Efficacy of Fluorouracil and Leucovorin, Fluorouracil and Levamisole, and Fluorouracil, Leucovorin, and Levamisole in Patients With Dukes' B and C Carcinoma of the Colon: Results From National Surgical Adjuvant Breast and Bowel Project C-04
- 1 November 1999
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (11), 3553-3559
- https://doi.org/10.1200/jco.1999.17.11.3553
Abstract
PURPOSE: To compare the efficacy of leucovorin-modulated fluorouracil (FU+LV) with that of fluorouracil and levamisole (FU+LEV) or with the combination of FU+LV and levamisole (FU+LV+LEV). PATIENTS AND METHODS: Between July 1989 and December 1990, 2,151 patients with Dukes' B (stage II) and Dukes' C (stage III) carcinoma of the colon were entered onto National Surgical Adjuvant Breast and Bowl Project protocol C-04. Patients were randomly assigned to receive FU+LV (weekly regimen), FU + LEV, or the combination of FU+LV+LEV. The average time on study was 86 months. RESULTS: A pairwise comparison between patients treated with FU+LV or FU+LEV disclosed a prolongation in disease-free survival (DFS) in favor of the FU+LV group (65% v 60%; P = .04); there was a small prolongation in overall survival that was of borderline significance (74% v 70%; P = .07). There was no difference in the pairwise comparison between patients who received FU+LV or FU+LV+LEV for either DFS (65% v 64%; P = .67) or overall survival (74% v 73%; P = .99). There was no interaction between Dukes' stage and the effect of treatment. CONCLUSION: In patients with Dukes' B and C carcinoma of the colon, treatment with FU+LV seems to confer a small DFS advantage and a borderline prolongation in overall survival when compared with treatment with FU+LEV. The addition of LEV to FU+LV does not provide any additional benefit over and above that achieved with FU+LV. These findings support the use of adjuvant FU+LV as an acceptable therapeutic standard in patients with Dukes' B and C carcinoma of the colon.Keywords
This publication has 11 references indexed in Scilit:
- Efficacy of adjuvant fluorouracil and folinic acid in colon cancerThe Lancet, 1995
- Fluorouracil plus Levamisole as Effective Adjuvant Therapy after Resection of Stage III Colon Carcinoma: A Final ReportAnnals of Internal Medicine, 1995
- The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03.Journal of Clinical Oncology, 1993
- Adjuvant Therapy for Patients With Colon and Rectal CancerPublished by American Medical Association (AMA) ,1990
- Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon CarcinomaNew England Journal of Medicine, 1990
- Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic.Journal of Clinical Oncology, 1989
- Designs for group sequential testsControlled Clinical Trials, 1984
- Asymptotically Efficient Rank Invariant Test ProceduresJournal of the Royal Statistical Society. Series A (General), 1972
- Regression Models and Life‐TablesJournal of the Royal Statistical Society: Series B (Methodological), 1972
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958